Clinical Trial

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Study acronym: LILAC-TIMI 76
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Protocol Amendment History 5 changes
notable Enrollment increased: 1900 -> 2500 participants 2026-07-14
notable Trial sites expanded: 734 -> 789 locations 2026-07-14
notable Primary completion pushed: 2026-08-31 -> 2027-12-30 2026-07-14
minor Completion pushed: 2026-10-31 -> 2027-12-30 2026-07-14
notable Trial sites expanded: 721 -> 734 locations 2026-04-01
Trial Details
NCT Number NCT05712200
Lead Sponsor Anthos Therapeutics, Inc.
Collaborators: Novartis Pharmaceuticals
Conditions Atrial Fibrillation (AF)
Enrollment 2,500 participants
Start Date 2022-12-27
Primary Completion 2027-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-13